Buccal Mucoadhesive DMT Dosing for Sustained Depression Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, particularly treatment-resistant depression, face challenges due to the fast onset and short duration of action of N, N-dimethyltryptamine (DMT), complicating the determination of a suitable administration regimen and dosage frequency, which is essential for maintaining therapeutic blood levels over an extended period.
Innovation Solution
Administering a mucoadhesive composition containing DMT or its pharmaceutically acceptable salt through transmucosal routes, such as buccal application, to achieve a DMT Tmax of about 0.3 h to about 2 h and a DMT Cmax of about 5 ng/mL to about 80 ng/mL, with a DMT AUClast of about 3 ng·h/mL to about 70 ng·h/mL, providing a reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) total score by at least about 50%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If DMT is administered via smoking or intravenous injection, then the onset of action is very fast, but the duration of effect is short
Solution Approach 1:
The patent uses mucoadhesive polymers as intermediaries to deliver DMT through the buccal mucosa. This mediator system allows DMT to be absorbed transmutcosally, achieving both fast onset (within minutes) and extended duration (hours to days) by controlling the release rate from the polymer matrix.
Solution Approach 2:
The patent changes the administration route from pulmonary/intravenous to buccal transmucosal, and modifies the physical state of DMT by incorporating it into mucoadhesive formulations. This parameter change enables sustained release while maintaining rapid onset through optimized polymer composition and delivery system design.
2Duration of action of moving object
If DMT is administered to achieve therapeutic blood levels over an extended period, then the treatment duration is improved, but the complexity of determining suitable administration regimen and dosage frequency increases
Solution Approach 1:
The mucoadhesive formulation provides continuous release of DMT over extended periods (hours to days), maintaining therapeutic blood levels without requiring frequent dosing. This continuous action simplifies the administration regimen by reducing the frequency of doses while ensuring sustained therapeutic effect.
Solution Approach 2:
The patent performs preliminary optimization of the mucoadhesive formulation composition and delivery system to predetermine effective dosage ranges and administration frequencies. This preliminary action establishes standardized regimens that simplify clinical implementation while achieving reliable therapeutic outcomes.
3Ease of manufacture
If current antidepressant medications are used, then the treatment approach is conventional and readily available, but the treatment takes weeks or months to achieve full effect
Solution Approach 1:
The patent replaces the conventional pharmacological mechanism (gradual neurotransmitter regulation over weeks/months) with a psychedelic compound delivery system that produces rapid therapeutic effects (within minutes to hours). This substitution fundamentally changes the mechanism of action while maintaining medication-based treatment availability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively treats treatment-resistant depression by maintaining therapeutic DMT levels for an extended period, leading to significant improvement in depression symptoms as measured by the MADRS scale.
Implementation Method 1
administering a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT)
Implementation Method 2
the composition is administered buccally... the composition is administered through a transmucosal application
Data Source
AI summary
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.